Long-term stability of bevacizumab repackaged in 1mL polypropylene syringes for intravitreal administration

Annales Pharmaceutiques Francaises

Volumn 70, Issue 3, 2012, Pages 139-154

  Paul, M ^a   Vieillard, V ^a   Roumi, E ^a   Cauvin, A ^a   Despiau, M C ^b   Laurent, M ^b   Astier, A ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

Author keywords

Bevacizumab; Intravitreal administration; Off label use; Ophthalmology; Stability

Indexed keywords

BEVACIZUMAB; POLYPROPYLENE; SILICONE OIL;

AMINO ACID SEQUENCE; ANALYTIC METHOD; ANTIBODY STRUCTURE; ARTICLE; CONTROLLED STUDY; DENATURATION; DIFFRACTION LASER SPECTROSCOPY; DRUG CONTAMINATION; DRUG PACKAGING; DRUG SAFETY; DRUG STABILITY; DRUG STORAGE; GEL PERMEATION CHROMATOGRAPHY; IMAGE ANALYSIS; INFRARED SPECTROSCOPY; ION EXCLUSION CHROMATOGRAPHY; MICROSCOPY; OFF LABEL DRUG USE; PEPTIDE MAPPING; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; RAMAN SPECTROMETRY; STORAGE TEMPERATURE; SYRINGE; THERMAL DENATURATION; TURBIDIMETRY; ULTRAVIOLET SPECTROSCOPY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHROMATOGRAPHY, GEL; DRUG COMPOUNDING; DRUG STABILITY; DRUG STORAGE; INJECTIONS; MACULAR DEGENERATION; NEPHELOMETRY AND TURBIDIMETRY; PEPTIDE MAPPING; PHARMACY SERVICE, HOSPITAL; POLYPROPYLENES; SPECTROPHOTOMETRY, INFRARED; SPECTROPHOTOMETRY, ULTRAVIOLET; SYRINGES; TEMPERATURE; VITREOUS BODY;

EID: 84861709468     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharma.2012.03.006     Document Type: Article

References (45)

1. Cursiefen C., Maruyama K., Liu Y., Chen L., Jackson D., Wiegand S., et al. Inhibition of hem- and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci 2004, 45:2666-2673.
2. Bock F., Onderka J., Dietrich T., Bachmann B., Kruse F.E., Paschke M., et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Br J Ophthalmol 2007, 91:804-807.
3. Bressler NM Anti-angiogenic approaches to age-related macular degeneration today. Ophtalmology 2009, 116(10):15-23.
4. Hubschman J.P., Reddy S., Schwartz S. Age-related macular degeneration: current treatments. Clin Ophthalmol 2009, 3:155-166.
5. Cohen S.Y. Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovacularization in pathologic myopia. Retina 2009, 29(8):1062-1066.
6. Schwartz SG, Flynn Jr HW. Pharmacotherapies for diabetic retinopathy: present and future. Exp Diabetes Res; 2007, Article ID 52487, doi:10.1155/2007/52487.
7. ®) for the management of anterior chamber neovascularisation and neovascular glaucoma. Clin Ophthalmol 2009, 3:685-688.
8. Fung A.E., Rosenfeld P.J., Reichel E The international intravitreal bevacizumab safety survey: using the Internet to assess drug safety worldwide. Br J Ophtalmol 2006, 90:1344-1349.
9. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. New Eng J Med 2011, 364:1897-1908. The CATT group.
10. http://www.aao.org/newsroom/release/20110428.cfm. Accédé le 3 janvier 2012.
11. ®) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing. Retina 2006, 26:519-522.
12. Liu L., Ammar D.A., Ross L.A., Mandava N., Kahook N.Y., Carpenter J.F. Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling. Invest Ophtalmol Vis Sci 2011, 52:1023-1034.
13. Kahook M.Y., Liu L., Ruzycki P., Mandava N., Carpenter J.F., Petrash J.M., et al. High molecular weight aggregates in repackaged bevacizumab. Retina 2010, 30:887-892.
14. Paul M., Lahlou A., Carvalho M., Blanchet B., Astier A. Thermal stability of two monoclonal antibodies: cetuximab and bevacizumab. Eur J Oncol Pharm 2008, 2(1):37.
15. Lahlou A., Blanchet B., Carvalho M., Paul M., Astier A. Mechanically-induced aggregation of the monoclonal antibody cetuximab. Ann Pharm Fr 2009, 67:340-352.
16. Mahler C., et al. Induction and analysis of aggregates in a liquid igG1-antibody formulation. Eur J Pharm Biopharm 2005, 59:407-417.
17. Bloomfield V.A. Static and dynamic light scattering from aggregating particles. Biopolymers 2000, 54:178-182.
18. Wang W. Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm 2005, 289:1-30.
19. Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm 1999, 185:129-188.
20. Lowe D., Dudgeon K., Rouet R., Schofiel P., Jermutus L., Christ D. Aggregation, stability and formulation of human antibody therapeutics. Adv Prot Chem Struct Biol 2011, 84:41-61.
21. Chi E.Y., Krishnan S., Randolph T.W., Carpenter J.F. Physical stability of proteins in aqueous solution: mechanism and driving force in nonnative protein aggregation. Pharm Res 2003, 20:1325-1336.
22. Jaenicke R. Stability and stabilization of globular proteins in solution. J Biotechnol 2000, 79:193-203.
23. Bieri O., Kiefhaber T. Elementary steps in protein folding. Biol Chem 1999, 380:923-929.
24. Thirumangalathu R., Sampathkumar K., Brems D., Randolph T., Carpentier J. Effects of pH, temperature, and sucrose on benzyl alcohol-induced aggregation of recombinant human granulocyte colony stimulating factor. J Pharm Sci 2006, 95:1480-1497.
25. Farruggia B., Garcia G., D'Angelo C., Pic G. Destabilization of human serum albumin by polyethylene glycols studied by thermodynamical equilibrium and kinetic approaches. Int J Biol Macromolecules 1997, 20:43-51.
26. Harn N., Allan C., Oliver C., Middaugh C.R. Highly concentrated monoclonal antibody solutions: direct analysis of physical structure and thermal stability. J Pharm Sci 2007, 96:532-546.
27. Cauchy M., D'Aoust S., Dawson B., Rode H., Hefford M.A. Thermal stability: a means to assure tertiary structure in therapeutic proteins. Biol J Int Assoc Biol Stand 2002, 30:175-185.
28. Kuelzo L.A., Ersoy B., Ralston J.P., Middaugh C.R. Derivative absorbance spectroscopy and protein phase diagrams as tools for comprehensive protein characterization: a bGCSF case study. J Pharm Sci 2003, 92:1805-1820.
29. Balestrieri C., Colonna G., Giovane A., Irace G., Servillo L. Second derivative spectroscopy of proteins. A method for the quantitative determination of aromatic amino acids in proteins. Eur J Biochem 1978, 90:433-440.
30. Ichikawa T., Terada H. Estimation of state and amount of phenylalanine residues in proteins by second derivative spectrophotometry. Biochim Biophys Acta 1979, 580:120-128.
31. Servillo L., Colonna G., Balestrieri C., Ragone R., Irace G. Simultaneous determination of tyrosine and tryptophan residues in proteins by second derivative spectroscopy. Anal Biochem 1982, 126:251-257.
32. Kong J., Yu S. Fourier transform infrared spectroscopic analysis of protein secondary structures. Acta Biochimica Biophysica Sinica 2007, 39:549-559.
33. Smith B.C. Fundamentals of Fourier transform infrared spectroscopy 1996, CRC Press, Boca Raton.
34. Krimm S., Bandekar J. Vibrational spectroscopy and conformation of peptides, polypeptides, and proteins. Adv Protein Chem 1986, 38:181-364.
35. Byler D.M. Resolution-enhanced Fourier transform infrared spectroscopy of enzymes. Methods Enzymol 1986, 130:290-311.
36. Moorhouse K.G., Nashabeh W., Deveney J., Bjork N.S., Mulkerrin M.G., Ryskamp T. Validation of an HPLC method for the analysis of the charge heterogeneity of the recombinant monoclonal antibody IDEC-C2B8 after papain digestion. J Pharm Biomed Anal 1997, 16:593-603.
37. Liu C., Vailhe C., Samuel N., Min Q. A simple and reproducible approach to characterize protein stability using rheology. Int J Pharm 2009, 374:1-4.
38. Usami A. The effect of pH, hydrogen peroxide and temperature on the stability of human monoclonal antibody. J Pharm Biomed Anal 1996, 14:1133-1140.
39. Cordoba A.J., Shyong B.J., Breen D., Harris R.J. Non-enzymatic hinge region fragmentation of antibodies in solution. J Chromatogr B Anal Technol Biomed Life Sci 2005, 818:115-121.
40. Sreedhara A., Glover Z.K., Piros N., Xiao N., Patel A., Kabakoff B. Stability of IgG1 monoclonal antibodies in intravenous infusion bags under clinical in-use conditions. J Pharm Sci 2011, 101:21-30.
41. Chanteleau E.A., Berger M. Pillution of insulin with silicone oil, a hazard of disposable plastic syringes. Lancet 1985, 1:1459.
42. Chanteleau E.A., Berger M., Bohlken B. Silicone oil release from disposable insulin syringes. Diabetes Care 1986, 9:672-673.
43. Jones L.S., Kaufmann A., Middaugh C.R. Silicone oil-induced aggregation of proteins. J Pharm Sci 2005, 94:918-927.
44. Thirumangalathu R., Krishnan S., Speed-Ricci M., Brems D.N., Randolph T.W., Carpenter J.F. Silicone oil-and agitation-induced aggregation of a monoclonal antibody in aqueous solution. J Pharm Sci 2009, 98:3167-3181.
45. Vermeer A.W.P., Norde W. The thermal stability of immunoglobulin: unfolding and aggregation of a multi-domain protein. Biophys J 2000, 78:394-404.